Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 10Breast Neoplasms 6Recurrence 4Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Hematologic Neoplasms 4Wilms Tumor 3Solid Tumor 3Neuroblastoma 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Basal Cell 3Testicular Neoplasms 2Skin Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neutropenia 2Mycosis Fungoides 2Mycoses 2Medical Oncology 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

Itraconazole 2roniciclib 1anetumab ravtansine 1Control Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Medical Oncology × Itraconazole × Clear all
NCT02824042 2020-07-31

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Bayer

Phase 1 Completed
63 enrolled

Medical Oncology

NCT02457351 2016-05-23

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Bayer

Phase 1 Completed
14 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡